Thymulin Analog (PAT) dosing & administration
Synthetic thymulin-derived nonapeptide with potent analgesic and anti-inflammatory properties
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Timing
Best time to take
Administer Thymulin Analog (PAT) at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Thymulin Analog (PAT) injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Thymulin Analog (PAT) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Thymulin Analog (PAT) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Thymulin Analog (PAT) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Intraperitoneal injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with Thymulin Analog (PAT). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Injection Site Reaction, Transient Immune Modulation, Mild Sedation, Short Duration of Action
Less common: Potential Immune Suppression, CNS Effects with Central Administration
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Thymulin Analog (PAT)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Thymulin Analog (PAT) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Strong Immunosuppressants — May compound immune suppression through overlapping anti-inflammatory mechanisms
- Nicotinic Receptor Antagonists — Alpha-7 nAChR antagonists like methyllycaconitine block PAT primary mechanism of action
- High-Dose Corticosteroids — Redundant anti-inflammatory pathways may confound research outcomes or cause excessive immune suppression
Published research
What the studies show
Safieh-Garabedian B, et al. · 2019
Thymulin-related peptides target inflammatory components in neuropathic pain by reducing cytokine-mediated neuroinflammation. These peptides regulate inflammatory mediators for novel therapeutic approaches to chronic pain.
Safieh-Garabedian B, et al. · 2013
PAT demonstrated anti-inflammatory action through potentiation of alpha-7 nicotinic acetylcholine receptors, reversing inflammatory nociceptive hyperactivity in rats. The mechanism differed from traditional analgesics.
Dardenne M, et al. · 2006
No abstract available for comprehensive analysis.
Saadé NE, et al. · 2003
Thymulin analog PAT produced powerful neuropathic pain reduction equal to morphine in chronic constriction and spared nerve injury models. Daily treatment progressively attenuated all neuropathic manifestations.
Safieh-Garabedian B, et al. · 2002
PAT significantly reduced inflammatory hyperalgesia in rats through dose-dependent decrease in pro-inflammatory cytokines. Analgesic effects matched dexamethasone and indomethacin.
Head to head
Thymulin Analog (PAT) compared
Want the full picture?
The complete Thymulin Analog (PAT) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.